Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Philadelphia, PA, Jan. 05, 2026 (GLOBE NEWSWIRE) -- DriveItAway Holdings, Inc. (OTC: DWAY) (“DriveItAway” or the “Company”), a digital mobility platform enabling flexible vehicle access and...
-
BROOKFIELD, News, Jan. 02, 2026 (GLOBE NEWSWIRE) -- Brookfield Renewable Partners L.P. (TSX: BEP.UN; NYSE: BEP) today announced that it intends to redeem all of its outstanding Class A Preferred...
-
NEW YORK, Jan. 02, 2026 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Tesco PLC (LSE:...
-
VANCOUVER, British Columbia, Dec. 31, 2025 (GLOBE NEWSWIRE) -- EquityInsider.com News Commentary — Gold developers are racing to advance construction decisions as record producer margins create a...
-
Extension Allows Additional Time to Meet Minimum Bid Price RequirementCompany Remains Focused on Compliance Strategy and Execution TEL AVIV, Israel, Dec. 30, 2025 (GLOBE NEWSWIRE) -- REE Automotive...
-
Washington, D.C., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Pending home sales in November jumped by 3.3% from the prior month and 2.6% year over year, according to the National Association of REALTORS®...
-
NESS ZIONA, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies...
-
TORONTO, 23 déc. 2025 (GLOBE NEWSWIRE) -- Placements Vanguard Canada Inc. a annoncé aujourd’hui les distributions annuelles définitives de gains en capital des FNB Vanguard énumérés ci-dessous...
-
TORONTO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vanguard Investments Canada Inc. today announced the final annual capital gains distributions for the Vanguard ETFs listed below for the 2025 tax...
-
FDA qualification of Total Hip BMD as a validated surrogate endpoint for novel osteoporosis drug development further bolsters Entera's July 2025 FDA alignment and regulatory strategy for EB613 ...